AAM’s Biosimilars Council Praises House Passage of the FDA Reauthorization Act of 2017

Sunday July 2, 2017

WASHINGTON, DC (July 12, 2017) – The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), issued the following statement regarding the U.S. House of Representative’s passage of the FDA Reauthorization Act of 2017:

“With today’s vote, the House has taken an important step toward bringing more life-saving biosimilar medicines to market over the next five years at a savings over expensive biologics,” said Biosimilars
Council Executive Director Christine Simmon. “This bill will help increase competition, ensuring that patients will have more timely access to safe, effective and affordable biosimilar medicines.”

The Generic Pharmaceutical Association (GPhA) is now AAM.

Read the Letter of Support

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.